In vivo activities of recombinant divercin V41 and its structural variants against Listeria monocytogenes

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 1, 2010, Pages 563-564

  Rihakova, Jitka ^a,b   Cappelier, Jean Michel ^a   Hue, Isabelle ^a   Demnerova, Katerina ^b   Fédérighi, Michel ^a   Prévost, Hervé ^a   Drider, Djamel ^a  

^a LUNAM UNIVERSITÉ   (France)

^b INSTITUTE OF CHEMICAL TECHNOLOGY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BACTERIOCIN; RECOMBINANT DIVERCIN RV41; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; FEMALE; IN VIVO STUDY; LISTERIA MONOCYTOGENES; LISTERIOSIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMINO ACIDS; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIOCINS; CULTURE MEDIA; FEMALE; LISTERIA INFECTIONS; LISTERIA MONOCYTOGENES; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; PEPTIDES; RECOMBINANT PROTEINS; SPLEEN;

EID: 73849126611     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00765-09     Document Type: Article

References (17)

1. Bhunia, A. K., M. C. Johnson, B. Ray, and E. L. Belden. 1990. Antigenic property of pediocin AcH produced by Pediococcus acidilactici H. J. Appl. Bacteriol. 69:211-215.
2. Calvez, S., A. Rincé, Y. Auffray, H. Prévost, and D. Drider. 2007. Identification of new genes associated with intermediate resistance of Enterococcus faecalis to divercin V41, a pediocin-like bacteriocin. Microbiology 153:1609-1618.
3. De Kwaadsteniet, M., K. T. Doeschate, and L. M. Dicks. 2009. Nisin F in the treatment of respiratory tract infections caused by Staphylococcus aureus. Lett. Appl. Microbiol. 48:65-70.
4. Glaser, P., L. Frangeul, C. Buchrieser, C. Rusniok, A. Amend, F. Baquero, P. Berche, H. Bloecker, P. Brandt, T. Chakraborty, A. Charbit, F. Chetouani, E. Couvé, A. de Daruvar, P. Dehoux, F. Domann, G. Domínguez-Bernal, E. Duchaud, L. Durant, O. Dussurget, K. D. Entian, H. Fsihi, F. García-del Portillo, P. Garrido, L. Gautier, W. Goebel, N. Gómez-López, T. Hain, J. Hauf, D. Jackson, L. M. Jones, U. Kaerst, J. Kreft, M. Kuhn, F. Kunst, G. Kurapkat, F. Madueno, A. Maitournam, J. M. Vicente, E. Ng, H. Nedjari, G. Nordsiek, S. Novella, B. de Pablos, J. C. Pérez-Diaz, R. Purcell, B. Remmel, M. Rose, T. Schlueter, N. Simoes, A. Tierrez, J. A. Vázquez-Boland, H. Voss, J. Wehland, and P. Cossart. 2001. Comparative genomics of Listeria species. Science 294:849-852.
5. Hof, H. 2004. An update on the medical management of listeriosis. Expert Opin. Pharmacother. 5:1727-1735.
6. Ingham, A., M. Ford, R. J. Moore, and M. Tizard. 2003. The bacteriocin piscicolin 126 retains antilisterial activity in vivo. J. Antimicrob. Chemother. 51:1365-1371.
7. Knoetze, H., S. D. Todorov, and L. M. Dicks. 2008. A class IIa peptide from Enterococcus mundtii inhibits bacteria associated with otitis media. Int. J. Antimicrob. Agents 31:228-234.
8. Pieterse, R., S. D. Todorov, and L. M. Dicks. 2008. Bacteriocin ST91KM, produced by Streptococcus gallolyticus subsp. macedonicus ST91KM, is a narrow-spectrum peptide active against bacteria associated with mastitis in dairy cattle. Can. J. Microbiol. 54:525-531.
9. Richard, C., A. Brillet, M. F. Pilet, H. Prévost, and D. Drider. 2003. Evidence on inhibition of Listeria monocytogenes by divercin V41 action. Lett. Appl. Microbiol. 36:288-292.
10. Richard, C., D. Drider, K. Elmorjani, D. Marion, and H. Prévost. 2004. Heterologous expression and purification of active divercin V41, a class IIa bacteriocin encoded by a synthetic gene in Escherichia coli. J. Bacteriol. 186:4276-4284.
11. Richard, C., R. Canon, K. Naghmouchi, D. Bertrand, H. Prévost, and D. Drider. 2006. Evidence on correlation between number of disulfide bridge and toxicity of class IIa bacteriocins. Food Microbiol. 23:175-183.
12. Rihakova, J., V. W. Petit, K. Demnerova, H. Prévost, S. Rebuffat, and D. Drider. 2009. Insights into structure-activity relationships in the C-terminal region of divercin V41, a class IIa bacteriocin with high-level antilisterial activity. Appl. Environ. Microbiol. 75:1811-1819.
13. Schlech, W. F. 2000. Foodborne listeriosis. Clin. Infect. Dis. 31:770-775.
14. Twisselmann, B. 2000. Epidemiology, treatment, and control of listeriosis. Euro Surveill. 4:pii=1611.
15. Wachsman, M. B., V. Castilla, A. P. de Ruiz Holgado, R. A. de Torres, F. Sesma, and C. E. Coto. 2003. Enterocin CRL35 inhibits late stages of HSV-1 and HSV-2 replication in vitro. Antiviral Res. 58:17-24.
16. Wachsman, M. B., M. E. Farías, E. Takeda, F. Sesma, A. P. de Ruiz Holgado, A. P. R. A. de Torres, and C. E. Coto. 1999. Antiviral activity of enterocin CRL35 against herpesviruses. Int. J. Antimicrob. Agents 12:293-299.
17. Wagner, M., and J. McLauchlin. 2008. Biology, p. 3-26. In D. Liu (ed.), Handbook of Listeria monocytogenes. CRC Press, Boca Raton, FL.